US healthcare providers, physician groups, specialty .

Strengths - Strong growth: Q1 FY27 revenue was ₹893.6 Cr, up 20.7% YoY. Business Standard - Q1 FY27 EBITDA reached ₹294.9 Cr, with a strong 33% EBITDA margin. Business Standard - PAT increased 27.8% YoY to ₹193.7 Cr; adjusted PAT increased 28%. Business Standard - Strong client relationships: the company had 600+ healthcare organisations and 85%+ revenue from repeat customers according to its Q1 presentation. Bazaar Watch - Large healthcare outsourcing opportunity in the US, with IKS positioned across the patient-care journey. Weaknesses - Significant dependence on the US healthcare market, creating geographic concentration. - Top-client concentration remains an important factor to monitor. - Healthcare regulations and data-privacy requirements increase compliance complexity. - Acquisitions can temporarily pressure margins and create integration challenges. - Large clinical/technology workforce means employee costs are an important operating expense. Opportunities - AI-driven healthcare automation can expand margins and increase the company's addressable market. - Revenue-cycle management, medical coding, clinical documentation and patient engagement remain large outsourcing opportunities. - TruBridge acquisition expands IKS's presence in rural/community healthcare and adds complementary capabilities. The acquisition was completed in July 2026. IKS Health - Cross-selling between IKS and TruBridge customer bases. Threats - AI disruption: competitors may develop more efficient healthcare automation platforms. - US healthcare policy and reimbursement changes can affect customer spending. - Data-security, cybersecurity and HIPAA-related risks. - Client concentration and loss of major contracts. - Competition from global IT/BPM companies and specialised healthcare-technology providers. - Acquisition integration and execution risk. - Wage inflation and shortage of specialised healthcare talent.